Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy

Michael S. Cookson, Neil E. Fleshner, Scott M. Soloway, William R. Fair

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objectives. Increasingly, nonpalpable prostate-specific antigen (PSA)- detected (Stage T1c) tumors are being treated with curative intent. Presently, only limited information is available regarding pathologic findings correlated with preoperative PSA levels. Herein, we report the characteristics of Stage T1c tumors in a contemporary surgical series. Methods. Clinical and pathologic results in 107 patients with Stage T1c tumors treated with radical prostatectomy were compared with those in 300 patients with palpable (Stage T2) tumors. Multivariate analysis was performed to determine which clinical variables independently predicted pathologic staging. Results. Stage T1c tumors were equivalent to Stage T2 tumors with respect to organ-confined and margin-positive rates, PSA level was the strongest independent predictor of extracapsular and margin-positive rates (P = 0.003]. The absence of palpability was not a significant predictor of pathologic outcome. Significantly higher rates of organ- and specimen- confined disease were seen in patients with PSA levels less than 10.0 ng/mL, particularly less than 7.0 ng/mL. Patients with serum PSA levels greater than 20 ng/mL were at high risk for positive margins (relative risk 5.42, P <0.001). Conclusions. Stage T1c tumors represent a heterogeneous group of cancers. These tumors are pathologically similar to Stage T2 tumors, and patients should be offered similar treatment options. PSA level was the strongest predictor of pathologic stage, irrespective of tumor palpability. These results suggest that efforts directed toward identifying cancers, including nonpalpable tumors, in patients with early PSA elevations may result in improved rates of organ-confined disease. The impact of treatment on Stage T1c tumors remains to be defined.

Original languageEnglish
Pages (from-to)887-893
Number of pages7
JournalUrology
Volume49
Issue number6
DOIs
StatePublished - Jun 1 1997
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Neoplasms
Multivariate Analysis

ASJC Scopus subject areas

  • Urology

Cite this

Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. / Cookson, Michael S.; Fleshner, Neil E.; Soloway, Scott M.; Fair, William R.

In: Urology, Vol. 49, No. 6, 01.06.1997, p. 887-893.

Research output: Contribution to journalArticle

Cookson, Michael S. ; Fleshner, Neil E. ; Soloway, Scott M. ; Fair, William R. / Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. In: Urology. 1997 ; Vol. 49, No. 6. pp. 887-893.
@article{7d5c62ce1c114ec9906363da36758c37,
title = "Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy",
abstract = "Objectives. Increasingly, nonpalpable prostate-specific antigen (PSA)- detected (Stage T1c) tumors are being treated with curative intent. Presently, only limited information is available regarding pathologic findings correlated with preoperative PSA levels. Herein, we report the characteristics of Stage T1c tumors in a contemporary surgical series. Methods. Clinical and pathologic results in 107 patients with Stage T1c tumors treated with radical prostatectomy were compared with those in 300 patients with palpable (Stage T2) tumors. Multivariate analysis was performed to determine which clinical variables independently predicted pathologic staging. Results. Stage T1c tumors were equivalent to Stage T2 tumors with respect to organ-confined and margin-positive rates, PSA level was the strongest independent predictor of extracapsular and margin-positive rates (P = 0.003]. The absence of palpability was not a significant predictor of pathologic outcome. Significantly higher rates of organ- and specimen- confined disease were seen in patients with PSA levels less than 10.0 ng/mL, particularly less than 7.0 ng/mL. Patients with serum PSA levels greater than 20 ng/mL were at high risk for positive margins (relative risk 5.42, P <0.001). Conclusions. Stage T1c tumors represent a heterogeneous group of cancers. These tumors are pathologically similar to Stage T2 tumors, and patients should be offered similar treatment options. PSA level was the strongest predictor of pathologic stage, irrespective of tumor palpability. These results suggest that efforts directed toward identifying cancers, including nonpalpable tumors, in patients with early PSA elevations may result in improved rates of organ-confined disease. The impact of treatment on Stage T1c tumors remains to be defined.",
author = "Cookson, {Michael S.} and Fleshner, {Neil E.} and Soloway, {Scott M.} and Fair, {William R.}",
year = "1997",
month = "6",
day = "1",
doi = "10.1016/S0090-4295(97)00107-6",
language = "English",
volume = "49",
pages = "887--893",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy

AU - Cookson, Michael S.

AU - Fleshner, Neil E.

AU - Soloway, Scott M.

AU - Fair, William R.

PY - 1997/6/1

Y1 - 1997/6/1

N2 - Objectives. Increasingly, nonpalpable prostate-specific antigen (PSA)- detected (Stage T1c) tumors are being treated with curative intent. Presently, only limited information is available regarding pathologic findings correlated with preoperative PSA levels. Herein, we report the characteristics of Stage T1c tumors in a contemporary surgical series. Methods. Clinical and pathologic results in 107 patients with Stage T1c tumors treated with radical prostatectomy were compared with those in 300 patients with palpable (Stage T2) tumors. Multivariate analysis was performed to determine which clinical variables independently predicted pathologic staging. Results. Stage T1c tumors were equivalent to Stage T2 tumors with respect to organ-confined and margin-positive rates, PSA level was the strongest independent predictor of extracapsular and margin-positive rates (P = 0.003]. The absence of palpability was not a significant predictor of pathologic outcome. Significantly higher rates of organ- and specimen- confined disease were seen in patients with PSA levels less than 10.0 ng/mL, particularly less than 7.0 ng/mL. Patients with serum PSA levels greater than 20 ng/mL were at high risk for positive margins (relative risk 5.42, P <0.001). Conclusions. Stage T1c tumors represent a heterogeneous group of cancers. These tumors are pathologically similar to Stage T2 tumors, and patients should be offered similar treatment options. PSA level was the strongest predictor of pathologic stage, irrespective of tumor palpability. These results suggest that efforts directed toward identifying cancers, including nonpalpable tumors, in patients with early PSA elevations may result in improved rates of organ-confined disease. The impact of treatment on Stage T1c tumors remains to be defined.

AB - Objectives. Increasingly, nonpalpable prostate-specific antigen (PSA)- detected (Stage T1c) tumors are being treated with curative intent. Presently, only limited information is available regarding pathologic findings correlated with preoperative PSA levels. Herein, we report the characteristics of Stage T1c tumors in a contemporary surgical series. Methods. Clinical and pathologic results in 107 patients with Stage T1c tumors treated with radical prostatectomy were compared with those in 300 patients with palpable (Stage T2) tumors. Multivariate analysis was performed to determine which clinical variables independently predicted pathologic staging. Results. Stage T1c tumors were equivalent to Stage T2 tumors with respect to organ-confined and margin-positive rates, PSA level was the strongest independent predictor of extracapsular and margin-positive rates (P = 0.003]. The absence of palpability was not a significant predictor of pathologic outcome. Significantly higher rates of organ- and specimen- confined disease were seen in patients with PSA levels less than 10.0 ng/mL, particularly less than 7.0 ng/mL. Patients with serum PSA levels greater than 20 ng/mL were at high risk for positive margins (relative risk 5.42, P <0.001). Conclusions. Stage T1c tumors represent a heterogeneous group of cancers. These tumors are pathologically similar to Stage T2 tumors, and patients should be offered similar treatment options. PSA level was the strongest predictor of pathologic stage, irrespective of tumor palpability. These results suggest that efforts directed toward identifying cancers, including nonpalpable tumors, in patients with early PSA elevations may result in improved rates of organ-confined disease. The impact of treatment on Stage T1c tumors remains to be defined.

UR - http://www.scopus.com/inward/record.url?scp=0030926567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030926567&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(97)00107-6

DO - 10.1016/S0090-4295(97)00107-6

M3 - Article

VL - 49

SP - 887

EP - 893

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -